Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II triAl of Cabozantinib for hepaTocellular carcInoma Patients intOlerant to Sorafenib Treatment or First Line Treatment Different to sorafeNib. (ACTION Trial)

NCT04316182 is registered in ClinicalTrials.gov with Fundacion Clinic per a la Recerca Biomédica as lead sponsor.

NCT NCT04316182
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04316182 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II triAl of Cabozantinib for hepaTocellular carcInoma Patients intOlerant to Sorafenib Treatment or First Line Treatment Different to sorafeNib. (ACTION Trial)
Lead sponsor
Fundacion Clinic per a la Recerca Biomédica
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2020
Completion date
February 22, 2023
Enrollment
24 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma